Treatment of Selected Solid Tumors
common.study.values.description
“Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors”
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
DPX-Survivac
SubQ injection (q9w)
Drug - Cyclophosphamide
PO (BID)
Drug - Pembrolizumab
IV Infusion (q3w)
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
common.study.values.clinical-trial-id
NCT03836352
participant.views.study.view.id
axkjze
